Cadherin-11 expression is upregulated in invasive human breast cancer

Pohlodek,Kamil; Tan,Yen  Y.; Singer,Christian  F.; Gschwantler‑Kaulich,Daphne

doi:10.3892/ol.2016.5236

Cadherin-11 expression is upregulated in invasive human breast cancer

Authors:
- Kamil Pohlodek
- Yen Y. Tan
- Christian F. Singer
- Daphne Gschwantler‑Kaulich
View Affiliations

Affiliations: Second Department of Gynecology and Obstetrics, Faculty of Medicine, Comenius University of Bratislava, 82606 Bratislava, Slovakia, Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, A‑1090 Vienna, Austria
Published online on: October 10, 2016 https://doi.org/10.3892/ol.2016.5236
Pages: 4393-4398
Copyright: © Pohlodek et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Loss of expression of cadherin-11 protein is correlated with a loss of epithelial phenotype and a gain in tumor cell proliferation and invasion. It has been hypothesized that cadherin-11 may be a molecular marker for a more aggressive subtype of breast cancer. The present study examined the expression of the mesenchymal gene/protein cadherin‑11 in malignant, benign and healthy breast cancer samples. A paraffin‑embedded tissue microarray of both malignant and benign/healthy breast tumor was used. Clinicopathological parameters, including age, grading, tumor size, hormone receptors and HER2 receptors status were obtained from patient medical records. Expression of cadherin‑11 was analyzed using the monoclonal mouse anti cadherin‑11 IgG2B clone. Total RNA was extracted from each breast cancer sample and subjected to semi‑quantitative RT‑PCR analysis for cadherin‑11. Cadherin‑11 was detected in 80/82 malignant breast cancer samples and in 33/70 non‑malignant tissue samples. Cadherin‑11 expression was observed to be predominantly localized to the membrane of tumor cells. When compared to healthy breast tissue biopsies, both cadherin‑11 mRNA and protein were demonstrated to be significantly overexpressed in breast carcinoma (P=0.040 and P<0.0001, respectively). Within malignant tumors, however, protein expression was not identified to be associated with other clinicopathological parameters. Our results indicate that cadherin‑11 expression is upregulated in malignant human breast cancer.

View Figures

View References

1	Knudsen KA and Wheelock MJ: Cadherins and the mammary gland. J Cell Biochem. 95:488–496. 2005. View Article : Google Scholar : PubMed/NCBI
2	Andrews JL, Kim AC and Hens JR: The role ad function of cadherins in the mammary gland. Breast Cancer Res. 14:2032012. View Article : Google Scholar : PubMed/NCBI
3	Farina AK, Bong YS, Feltes CM and Byers SW: Post-transcriptional regulation of cadherin-11 expression by GSK-3 and beta-catenin in prostate and breast cancer cells. PLoS One. 4:e47972009. View Article : Google Scholar : PubMed/NCBI
4	Albergaria A, Ribeiro AS, Vieira AF, Sousa B, Nobre AR, Seruca R, Schmitt FC and Paredes J: P-cadherin role in normal breast development and cancer. Int J Dev Biol. 55:811–822. 2011. View Article : Google Scholar : PubMed/NCBI
5	Tamura D, Hiraga T, Myoui A, Yoshikawa H and Yoneda T: Cadherin-11-mediated interactions with bone marrow stromal/osteoblastic cells support selective colonization of breast cancer cells in bone. Int J Oncol. 33:17–24. 2008.PubMed/NCBI
6	Pishvaian MJ, Feltes CM, Thompson P, Bussemakers MJ, Schalken JA and Byers SW: Cadherin-11 is expressed in invasive breast cancer cell lines. Cancer Res. 59:947–952. 1999.PubMed/NCBI
7	Berx G and van Roy F: Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol. 1:a0031292009. View Article : Google Scholar : PubMed/NCBI
8	Maeda M, Johnson KR and Wheelock MJ: Cadherin switching: Essential for behavioral but not morphological changes during epithelium-to-mesenchyme transition. J Cell Sci. 118:873–887. 2005. View Article : Google Scholar : PubMed/NCBI
9	Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428. 2009. View Article : Google Scholar : PubMed/NCBI
10	Lee DM, Kiener HP, Agarwal SK, Noss EH, Watts GF, Chisaka O, Takeichi M and Brenner MB: Cadherin-11 in synovial lining formation and pathology in arthritis. Science. 315:1006–1010. 2007. View Article : Google Scholar : PubMed/NCBI
11	Huang CF, Lira C, Chu K, Bilen MA, Lee YC, Ye X, Kim SM, Ortiz A, Wu FL, Logothetis CJ, et al: Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblasts. Cancer Res. 70:4580–4589. 2010. View Article : Google Scholar : PubMed/NCBI
12	Nieto MA: Epithelial-mesenchymal transitions in development and disease: Old views and new perspectives. Int J Dev Biol. 53:1541–1547. 2009. View Article : Google Scholar : PubMed/NCBI
13	Sarrió D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G and Palacios J: Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 68:989–997. 2008. View Article : Google Scholar : PubMed/NCBI
14	Chao YL, Shepard CR and Wells A: Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol Cancer. 9:1792010. View Article : Google Scholar : PubMed/NCBI
15	Clevers H and Nusse R: Wnt/ß-catenin signaling and disease. Cell. 149:1192–1205. 2012. View Article : Google Scholar : PubMed/NCBI
16	Dubois-Marshall S, Thomas JS, Faratian D, Harrison DJ and Katz E: Two possible mechanisms of epithelial to mesenchymal transition in invasive ductal breast cancer. Clin Exp Metastasis. 28:811–818. 2011. View Article : Google Scholar : PubMed/NCBI
17	Aceto N, Toner M, Maheswaran S and Haber D: En route to metastasis: Circulating tumor cell clusters and epithelial-to-mesenchymal transition. Trends in Cancer. 1:44–52. 2015. View Article : Google Scholar
18	Satcher RL, Pan T, Cheng CJ, Lee YC, Lin SC, Yu G, Li X, Hoang AG, Tamboli P, Jonasch E, et al: Cadherin-11 in renal cell carcinoma bone metastasis. PLoS One. 9:e898802014. View Article : Google Scholar : PubMed/NCBI
19	Li Y, Chao F, Huang B, Liu D, Kim J and Huang S: HOXC8 promotes breast tumorigenesis by transcriptionally facilitating cadherin-11 expression. Oncotarget. 5:2596–2607. 2014. View Article : Google Scholar : PubMed/NCBI
20	Alimperti S and Andreadis ST: CDH2 and CDH11 act as regulators of stem cell fate decisions. Stem Cell Res. 14:270–282. 2015. View Article : Google Scholar : PubMed/NCBI
21	Assefnia S, Dakshanamurthy S, Auvil JM Guidry, Hampel C, Anastasiadis PZ, Kallakury B, Uren A, Foley DW, Brown ML, Shapiro L, et al: Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: Common target, common therapies. Oncotarget. 5:1458–1474. 2014. View Article : Google Scholar : PubMed/NCBI
22	Dakshanamurthy S, Issa NT, Assefnia S, Seshasayee A, Peters OJ, Madhavan S, Uren A, Brown ML and Byers SW: Predicting new indications for approved drugs using a proteochemometric method. J Med Chem. 55:6832–6848. 2012. View Article : Google Scholar : PubMed/NCBI
23	Remmele W and Schicketanz KH: Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Pathol Res Pract. 189:862–866. 1993. View Article : Google Scholar : PubMed/NCBI
24	Hicks DG and Schiffhauer L: Standardized assessment of the HER2 status in breast cancer by immunohistochemistry. Lab Med. 42:459–467. 2011. View Article : Google Scholar
25	Savci-Heijink CD, Halfwerk H, Hooijer GK, Horlings HM, Wesseling J and van de Vijver MJ: Retrospective analysis of metastatic behaviour of breast cancer subtypes. Breast Cancer Res Treat. 150:547–557. 2015. View Article : Google Scholar : PubMed/NCBI
26	Salmen J, Neugebauer J, Fasching PA, Haeberle L, Huober J, Wöckel A, Rauh C, Schuetz F, Weissenbacher T, Kost B, et al: Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies. Breast Cancer Res Treat. 148:143–151. 2014. View Article : Google Scholar : PubMed/NCBI
27	Sun JY, Wu SG, Li FY, Lin HX and He ZY: Progesterone receptor loss identifies hormone receptor-positive and HER2-negative breast cancer subgroups at higher risk of relapse: A retrospective cohort study. Onco Targets Ther. 9:1707–1713. 2016.PubMed/NCBI
28	van Roy F: Beyond E-cadherin: Roles of other cadherin superfamily members in cancer. Nat Rev Cancer. 14:121–134. 2014. View Article : Google Scholar : PubMed/NCBI